FY2026 EPS Estimate for Journey Medical Lowered by Analyst

Journey Medical Corporation (NASDAQ:DERM) – Stock analysts at HC Wainwright lowered their FY2026 earnings per share estimates for shares of Journey Medical in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($0.06) for the year, down from their prior forecast of ($0.05). The consensus estimate for Journey Medical’s current full-year earnings is ($0.02) per share.

Journey Medical (NASDAQ:DERM) last released its earnings results on Wednesday, August 12th. The company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.01. The firm had revenue of $18.51 million during the quarter, compared to the consensus estimate of $18.36 million. Journey Medical had a negative return on equity of 20.23% and a negative net margin of 8.95%.

Several other research firms have also recently weighed in on DERM. Wall Street Zen raised shares of Journey Medical from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. B. Riley Financial reissued a “buy” rating and issued a $15.00 target price (up from $12.00) on shares of Journey Medical in a report on Thursday, August 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Journey Medical in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Journey Medical presently has a consensus rating of “Hold” and an average target price of $14.00.

Journey Medical Stock Up 3.1%

Shares of NASDAQ DERM opened at $6.66 on Monday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.41 and a current ratio of 1.59. Journey Medical has a 52 week low of $4.31 and a 52 week high of $9.56. The stock has a market capitalization of $183.35 million, a P/E ratio of -30.27 and a beta of 1.08. The stock’s fifty day moving average is $6.63 and its 200 day moving average is $6.57.

Institutional Investors Weigh In On Journey Medical

A number of hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE increased its position in Journey Medical by 4,707.0% during the 2nd quarter. Bank of America Corp DE now owns 4,134 shares of the company’s stock worth $30,000 after purchasing an additional 4,048 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Journey Medical in the second quarter valued at approximately $36,000. Royal Bank of Canada boosted its position in Journey Medical by 42.7% in the first quarter. Royal Bank of Canada now owns 8,175 shares of the company’s stock valued at $38,000 after buying an additional 2,446 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in shares of Journey Medical during the second quarter worth $41,000. Finally, Cetera Investment Advisers bought a new stake in shares of Journey Medical during the first quarter worth $48,000. 7.25% of the stock is currently owned by institutional investors and hedge funds.

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.